<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800107</url>
  </required_header>
  <id_info>
    <org_study_id>1682516</org_study_id>
    <nct_id>NCT04800107</nct_id>
  </id_info>
  <brief_title>Effect of Highly Bioavailable Curcumin on Subjective Tinnitus</brief_title>
  <official_title>Effect of Highly Bioavailable Curcumin on Subjective Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascension South East Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascension South East Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effectiveness of highly bioavailable curcumin in suppressing&#xD;
      subjective tinnitus based on pre- and post-treatment evaluations using the validated Tinnitus&#xD;
      Functional Index (TFI) and Tinnitus Handicap Inventory (THI) surveys.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with severe, subjective tinnitus due to sensorineural hearing loss will complete&#xD;
      both TFI and THI surveys prior to starting therapy. Subjects will then be randomized to a&#xD;
      treatment or placebo group. The treatment group will be provided with a supply of capsules&#xD;
      containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of&#xD;
      boswellia-phosphatidylcholine, which increases curcumin bioavailability. Subjects in the&#xD;
      treatment arm will be instructed to take 1 capsule by mouth twice daily for 30 days. Placebo&#xD;
      group subjects will be provided with a placebo compound with instructions to take the same&#xD;
      number of capsules by mouth for the same period of time. Both the active compound and the&#xD;
      placebo will be provided by Smartceuticals, Inc (910 W. Van Buren St. Ste 100-376 Chicago, IL&#xD;
      60607) to the outpatient pharmacy at Ascension Providence Park (Novi, MI), which will be&#xD;
      responsible for storage, distribution and tracking. After 30 days, patients will be asked to&#xD;
      return bottles to the pharmacy with any unused capsules to confirm and monitor compliance.&#xD;
      Placebo and active agent capsules and bottles will be identical in appearance with the&#xD;
      exception of a unique alphanumeric code on the bottle label that identifies whether the&#xD;
      distributed capsules contain active agent or placebo. This code will be matched to the&#xD;
      participating subject by the pharmacy and will be used at the end of the study to determine&#xD;
      which treatment arm each subject was in. To facilitate blinding, the master list of&#xD;
      alphanumeric codes will be maintained by the manufacturer. At the completion of therapy,&#xD;
      subjects from both groups will re-take the TFI and THI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Subjects will be randomized to a treatment or placebo group after completing both the TFI and THI surveys.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change on the Tinnitus Functional Index (TFI)</measure>
    <time_frame>Evaluate at the beginning of the trial and at the end of the 30 day treatment period.</time_frame>
    <description>Administer the TFI survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine Changes in the Tinnitus Handicap Inventory (THI)</measure>
    <time_frame>Evaluate at the beginning of the trial and at the end of the 30 day treatment period.</time_frame>
    <description>Measure the Tinnitus Handicap Inventory.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Tinnitus, Subjective</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl. Subjects will take 1 capsule by mouth twice daily for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be provided with a placebo compound with instructions to take 1 capsule by mouth twice daily for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Curcumin-phosphatidylcholine</intervention_name>
    <description>500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Tumeric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with subjective tinnitus due to sensorineural hearing loss as determined by&#xD;
             routine audiogram.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults with subjective tinnitus due to another cause&#xD;
&#xD;
          -  Sensitivity or allergy to test compounds&#xD;
&#xD;
          -  Use of other off-label medications, substances, treatments specifically for tinnitus&#xD;
             mitigation (e.g., anti-depressant/anxiety medications, GABA-inhibitors,&#xD;
             psychiatric-based interventions/counseling)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients taking anticoagulants to minimize risk of drug-drug interactions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seilish Babu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan Ear Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seilish Babu, MD</last_name>
    <phone>(248) 865-4444</phone>
    <email>sbabu@michiganear.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karl Doerfer, MD</last_name>
    <phone>(248) 865-4444</phone>
    <email>kdoerfer@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Michigan Ear Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seilesh Babu, M.D.</last_name>
      <phone>248-865-4444</phone>
      <email>sbabu@michiganear.com</email>
    </contact>
    <contact_backup>
      <last_name>Karl Doerfer, MD</last_name>
      <phone>(248) 865-4444</phone>
      <email>kdoerfer@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Michigan Ear Institute</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seilish Babu, MD</last_name>
      <phone>248-865-4444</phone>
      <email>sbabu@michiganear.com</email>
    </contact>
    <contact_backup>
      <last_name>Karl Doerfer, MD</last_name>
      <phone>(248) 865-4444</phone>
      <email>kdoerfer@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Michigan Ear Institute</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SeIlish Babu, MD</last_name>
      <phone>248-865-4444</phone>
      <email>sbabu@michiganear.com</email>
    </contact>
    <contact_backup>
      <last_name>Karl Doerfer, MD</last_name>
      <phone>(248) 865-4444</phone>
      <email>kdoerfer@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Soyalıç H, Gevrek F, Karaman S. Curcumin protects against acoustic trauma in the rat cochlea. Int J Pediatr Otorhinolaryngol. 2017 Aug;99:100-106. doi: 10.1016/j.ijporl.2017.05.029. Epub 2017 Jun 5.</citation>
    <PMID>28688549</PMID>
  </reference>
  <reference>
    <citation>Haryuna TS, Riawan W, Nasution A, Ma'at S, Harahap J, Adriztina I. Curcumin Reduces the Noise-Exposed Cochlear Fibroblasts Apoptosis. Int Arch Otorhinolaryngol. 2016 Oct;20(4):370-376. Epub 2016 Mar 4.</citation>
    <PMID>27746842</PMID>
  </reference>
  <reference>
    <citation>Soyalıç H, Gevrek F, Koç S, Avcu M, Metin M, Aladağ İ. Intraperitoneal curcumin and vitamin E combination for the treatment of cisplatin-induced ototoxicity in rats. Int J Pediatr Otorhinolaryngol. 2016 Oct;89:173-8. doi: 10.1016/j.ijporl.2016.08.012. Epub 2016 Aug 24.</citation>
    <PMID>27619052</PMID>
  </reference>
  <reference>
    <citation>Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother. 2017 Jan;85:102-112. doi: 10.1016/j.biopha.2016.11.098. Epub 2016 Dec 5. Review.</citation>
    <PMID>27930973</PMID>
  </reference>
  <reference>
    <citation>Yamaguchi T, Yoneyama M, Onaka Y, Imaizumi A, Ogita K. Preventive effect of curcumin and its highly bioavailable preparation on hearing loss induced by single or repeated exposure to noise: A comparative and mechanistic study. J Pharmacol Sci. 2017 Aug;134(4):225-233. doi: 10.1016/j.jphs.2017.07.003. Epub 2017 Aug 8.</citation>
    <PMID>28826625</PMID>
  </reference>
  <reference>
    <citation>Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013 Jan;15(1):195-218. doi: 10.1208/s12248-012-9432-8. Epub 2012 Nov 10. Review.</citation>
    <PMID>23143785</PMID>
  </reference>
  <reference>
    <citation>Castañeda R, Natarajan S, Jeong SY, Hong BN, Kang TH. Traditional oriental medicine for sensorineural hearing loss: Can ethnopharmacology contribute to potential drug discovery? J Ethnopharmacol. 2019 Mar 1;231:409-428. doi: 10.1016/j.jep.2018.11.016. Epub 2018 Nov 12. Review.</citation>
    <PMID>30439402</PMID>
  </reference>
  <reference>
    <citation>Meikle MB, Henry JA, Griest SE, Stewart BJ, Abrams HB, McArdle R, Myers PJ, Newman CW, Sandridge S, Turk DC, Folmer RL, Frederick EJ, House JW, Jacobson GP, Kinney SE, Martin WH, Nagler SM, Reich GE, Searchfield G, Sweetow R, Vernon JA. The tinnitus functional index: development of a new clinical measure for chronic, intrusive tinnitus. Ear Hear. 2012 Mar-Apr;33(2):153-76. doi: 10.1097/AUD.0b013e31822f67c0. Erratum in: Ear Hear. 2012 May;33(3):443.</citation>
    <PMID>22156949</PMID>
  </reference>
  <reference>
    <citation>Zeman F, Koller M, Figueiredo R, Aazevedo A, Rates M, Coelho C, Kleinjung T, de Ridder D, Langguth B, Landgrebe M. Tinnitus handicap inventory for evaluating treatment effects: which changes are clinically relevant? Otolaryngol Head Neck Surg. 2011 Aug;145(2):282-7. doi: 10.1177/0194599811403882.</citation>
    <PMID>21493265</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Curcumin</keyword>
  <keyword>Anti-inflammatory compound</keyword>
  <keyword>Turmeric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

